

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)		ATTORNEY'S DOCKET NUMBER X-15582	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) 10/524960	
INTERNATIONAL APPLICATION NO. PCT/US2003/023260	INTERNATIONAL FILING DATE 12 August 2003 (12.08.03)	PRIORITY DATE CLAIMED 22 August 2002 (22.08.02)	
TITLE OF INVENTION: MUSCARINIC AGONISTS			
APPLICANT(S) FOR DO/EO/US: Julie Kay Bush and Perry Clark Heath			
Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information:			
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.		
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.		
3.	<input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).		
4.	<input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.		
5.	<input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))		
	a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).		
	b. <input type="checkbox"/> has been transmitted by the International Bureau.		
	c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).		
6.	<input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).		
7.	<input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))		
	a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).		
	b. <input type="checkbox"/> have been transmitted by the International Bureau.		
	c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.		
	d. <input checked="" type="checkbox"/> have not been made and will not be made.		
8.	<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).		
9.	<input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).		
10.	<input checked="" type="checkbox"/> A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form.		
11.	<input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)).		
Items 12. to 18. below concern document(s) or information included:			
12.	<input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.		
13.	<input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.		
14.	<input type="checkbox"/> Assignment has been recorded at reel _____, frame _____.		
15.	<input checked="" type="checkbox"/> A FIRST preliminary amendment.		
	<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.		
16.	<input type="checkbox"/> A Sequence Listing, 1.821 Statement, and diskette.		
17.	<input checked="" type="checkbox"/> A power of attorney and other documents.		
18.	<input checked="" type="checkbox"/> Other items or information:		
Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for PCT/US2003/023260, filed 12 August 2003 which, claims the benefit, under 35 USC 119(e), of US provisional application 60/405,443, filed 22 August 2002."			

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.53)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
10/524960		PCT/US2003/023260		X-15582	
19.	<input checked="" type="checkbox"/> The following fees are submitted:	CALCULATIONS PTO USE ONLY			
Basic National Stage Fee = \$ 300.00					
National Stage Search Fee = \$ 500.00					
National Stage Examination Fee = \$ 200.00					
TOTAL NATIONAL STAGE FEES \$1,000.00 (a)					
Application Length Fee					
Total Length (excluding sequence listings)					
20 - 100 = excess pages (b)					
No extra charge for first 100 pages. Must pay \$250 for each adtl 50 pages (or fraction thereof).					
ENTER APPROPRIATE AMOUNT (a + b) =		\$ 1,000.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	20 - 20 =	0	X \$50.00		
Independent claims	8 - 3 =	5	X \$200.00	\$ 1,000.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$ 360.00	
TOTAL OF ABOVE CALCULATIONS =			\$ 1,360.00		
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).			\$		
SUBTOTAL =			\$ 2,360.00		
Processing fee of \$130.00 for furnishing English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$		
TOTAL NATIONAL FEE =			\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).			\$		
+ \$40.00 per property					
TOTAL FEES ENCLOSED =			\$ 2,360.00		
			Amount to be refunded	\$	
			charged	\$	
a.	<input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed.				
b.	<input checked="" type="checkbox"/> Please charge my Deposit Account No. 05-0840 in the amount of \$2,360.00 to cover the above fees. A duplicate copy of this sheet is enclosed.				
c.	<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.				
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: ELI LILLY AND COMPANY PATENT DIVISION P.O. BOX 6288 INDIANAPOLIS, INDIANA 46206-6288 February 18, 2005 Date 51,820 REGISTRATION NUMBER					
SIGNATURE Danica Hostettler NAME (317) 276-3711 TELEPHONE NUMBER					
25885 PATENT TRADEMARK OFFICE					

IN THE UNITED STATES RECEIVING OFFICE (USRO)

Applicants: Julie Kay Bush and Perry Clark Heath
International Application No.: PCT/US2003/023260
Filed: 12 August 2003 (12.08.03)
Invention: MUSCARINIC AGONISTS
Lilly Reference: X-15582
Earliest Priority Date: 22 August 2002 (22.08.02)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number: EL832893862US
Date of Deposit: 18 FEB. 2005

I hereby certify that the following attached paper or fee Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Queen Thomas
(Typed or printed name of person mailing paper)

Queen Thomas
(Signature of person mailing paper or fee)

CERTIFICATE UNDER 37 CFR 3.73(b)

Applicant: Julie Kay Bush and Perry Clark Heath

Application No.: US Nat'l Phase of PCT/US2003/023260 Filed: 12 August 2003

Entitled: MUSCARINIC AGONISTS

ELI LILLY AND COMPANY, a CORPORATION
(Name of Assignee) (Type of Assignee, e.g. corporation, partnership, university, government agency, etc.)

certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application identified above.

- ☐ The assignment was recorded in the Patent and Trademark Office at Reel _____, Frame _____.
☒ The assignment is being submitted separately for recordation; a copy of this assignment is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

February 18, 2005
Date

Danica Hostettler
Patent Attorney